During the treatment of lorlatinib, special attention should be paid to adverse reactions such as central nervous system side effects, hyperlipidemia, and weight gain. These reactions are usually manageable, but need to be monitored and intervened in a timely manner, and the dosage may be adjusted or discontinued as necessary to ensure medication safety.

Central nervous system side effects

Loratinib may trigger central nervous system reactions such as epilepsy, cognitive impairment, and emotional fluctuations, with a median onset time of 1.4 months. The symptoms are usually intermittent, mostly mild, and can be relieved by adjusting the dosage.

(1) Symptom manifestations

Including mental symptoms such as memory impairment, depression, anxiety, suicidal tendencies, as well as speech disorders, sleep disturbances, etc. The time span for the first onset ranges from 1 day to 3.4 years.

(2) Management measures

Grade 1 reactions can be maintained at the original dose or restored after a pause; Levels 2-3 need to be paused until symptoms improve and then reduced; Level 4 requires permanent discontinuation of medication. Patients should avoid driving or operating machinery.

2 Hyperlipidemia

Loratinib can cause elevated cholesterol and triglycerides, and regular monitoring of blood lipid levels is necessary before and 1-2 months after treatment. If necessary, lipid-lowering therapy should be initiated.

(1) Graded processing

Grade 4 hyperlipidemia requires suspension of medication until recovery is ≤ Grade 2; Relapse patients need to reduce their dosage. If lipid-lowering therapy is ineffective, consider permanently discontinuing the medication.

(2) Monitoring frequency

After baseline examination, monthly testing will be conducted for 1-2 months, followed by regular follow-up based on clinical conditions. Individuals with combined cardiovascular risks need to strengthen monitoring.

3 Weight gain

Although not explicitly listed as an independent adverse reaction, hyperlipidemia and metabolic abnormalities may lead to weight changes. It is recommended to regularly monitor weight and combine it with diet and exercise management.

(1) Related factors

May be related to drug-induced insulin resistance and lipid metabolism disorders. It is necessary to distinguish weight fluctuations caused by tumor treatment response.

(2) Intervention strategy

When abnormal weight gain occurs, evaluate metabolic indicators and adjust lipid-lowering plans if necessary. For severe cases, dosage adjustment or suspension of administration should be considered.